Member Info for Moneymunch

Genflow are on a one way trajectory from small cap to mid cap, multiple material newsflow and potential multiple game changing lucrative commercial licensing deals across the cutting edge science Sirt6 Gene Therapy Platform. Gla holders...On and UP and Away!!! :-)

Negotiating from a position of strength: Genflow Biosciences CEO explains AGM RNS

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company’s latest RNS regarding its upcoming AGM and the strategic rationale behind authorising the potential issuance of shares ahead of clinical partnership discussions.

Leire addressed potential shareholder concerns, acknowledging that announcements involving share issuance can sometimes be interpreted as a fundraising signal. However, he clarified that the RNS is not about launching a capital raise, but about strengthening the company’s position in ongoing and future negotiations with major pharmaceutical partners.

He explained that in biotech, financial flexibility translates directly into leverage. “In biotech, cash is not just money, it's negotiating power,” Leire said. As a public company, Genflow's financial position is visible to potential partners, and Leire emphasised the importance of maintaining the ability to walk away from unfavourable terms.

He added that the company is not committing to using the full 38% share issuance authority and stressed that the underlying science remains unchanged. “Our science has not changed. What we're doing is just making sure that we capture the full value of our science,” he noted.

While acknowledging that markets dislike uncertainty, Leire stated that uncertainty is temporary, whereas signing a bad deal would have lasting consequences. He said the company is focused on optimising for the best long-term outcome and ensuring it is not forced into a suboptimal agreement.

Negotiating from a position of strength: Genflow Biosciences CEO explains AGM RNS hxxps://share.google/asZZX9Npk24R626sN

More compelling research on Sirt6's panacea potential. Gla :-)

How a Sirtuin Protects Against Brain Diseases

Too many proteins overwhelm cellular maintenance.

February 23, 2026

Without SIRT6, the nucleoli in the nucleus expand and overproduce ribosomal RNA.

This overproduction leads to an increase in overall protein production, overwhelming maintenance machinery.

This leads to an increase in protein aggregates, which are the core culprits in neurodegenerative diseases such as Alzheimer’s.

In Aging Cell, researchers have explained how the sirtuin SIRT6 protects against proteostasis-related brain disorders by maintaining the function of nucleoli and limiting protein production.

How a Sirtuin Protects Against Brain Diseases hTtps://share.google/AfLbDmK8e8t3wOf9W

They're only seeking shareholder approval/ authorisation, and Eric has stated this will provide leverage and strengthen their position in any commercial licensing discussions, although they must be very low on cash at this point, and so a huge relief the €4m non-dilutive grant funding money has finally been signed off, with a tranche on its way by May, and if they go ahead with the fund raise, then 1.9p would be well received , and no dilution as such as the new shares will be going to tight hands, existing Major shareholders, the BoD and new investors (s) who could be highly significant to proceedings, and conceivably include a commercial partner, who wants a stake in the company, to accompany their multi-hundred million dollar licensing deal!!!??? Gl :-)

GM-Notice-February-2026.pdf https://share.google/aGWmIStCF6kBcGPJl

Hi Steg, found it on the Genflow website earlier after a bit of digging, £1.795m ÷ 94,473,684 = 1.9p a share, which personally I'm very happy about and no doubt higher than others are expecting. Gl :-)

Notice of General Meeting

Dear Shareholder,

Introduction

I am writing as the board of directors of the Company (the “Board”) is considering potentially undertaking an

equity raise to raise up to an aggregate of £1,795,000, which would be structured by issuing rights over the New

Shares (in the form of shares or warrants) to new investors and/or existing shareholders in the Company for cash

consideration in one or more private placements on a non-pre-emptive basis (the “Potential Equity Raise”).

The purpose of this Document is to provide you with information about the background to and reasons for thePotential Equity Raise, to explain why the Board considers a Potential Equity Raise to be in the best interests of the Company and its Shareholders as a whole, and why the Directors recommend that you vote in favour of the resolutions to be proposed at the General Meeting, notice of which is set out at Part II of this Document

..........

In order to facilitate the Potential Equity Raise and to ensure that it could be swiftly concluded if it progresses, the

Board is seeking specific shareholder approval at the General Meeting for the allotment and issue of up to 188,947,368 New Shares (which is approximately 38% of the Company’s current issued share capital) in connection with the Potential Equity Raise, on terms that the Board may determine.

This has been calculated on the following basis: 94,473,684 to be issued as New Ordinary Shares and a one for one warrant.

I'm not expecting any news until shareholder approval is confirmed 2nd March. They're looking to raise £1.795m with the issue of 94,473,684 new shares, to new investors, existing shareholders including the BoD, and a warrant with each share amounts to the 188,947,636 number highlighted in the GM RNS, and so the new shares should be confirmed and issued at a price of 1.9p a share....all bodes well for a fully funded Genflow moving forward, and a tranche of the €4m non-dilutive grant expected by May at the latest, and so maybe a payment of around €2m at least, as all of 2025 R&D costs were in consideration. A very exciting period beckons, multiple material newsflow, imminent funding, Patent Validation UPdate 18th March and comprehensive endpoint data from the Dog Trial by end of April.... Gla holders, a game-changing lucrative commercial licensing deal could be close!!! :-)

12/2/26

The biotechnology company, which focuses on developing gene therapies for age-related diseases, said the randomised, blinded study enrolled 24 beagle dogs aged over 10 years and was conducted by an independent contract research organisation.

Researchers allocated the dogs to four groups comprising two naked DNA treatment cohorts at different dose levels, a single-dose AAV8 cohort and a control group.

Interim analysis covered outcomes observed during the dosing period, with additional endpoints still under assessment.

All treatment groups demonstrated superior survival compared with the control group during the dosing period, and no adverse events were observed, the company said.

Genflow said all treatments exhibited a favourable safety and tolerability profile suitable for use in aged companion animals.

Across treatment cohorts, researchers observed improvements in several functional and observable endpoints, including quality of life, muscle mass preservation, frailty index reduction and coat quality, relative to control animals, which exhibited expected age-related decline.

Several key endpoints remain under evaluation, including biological age determination using methylation clock analysis and comprehensive muscle biopsy histology, which the company said were intended to provide further mechanistic and quantitative validation of the therapy’s effects.

Genflow said it expected to provide a comprehensive update on all remaining endpoints within approximately two months.

Company executives said the preliminary results supported the potential of the SIRT6 gene therapy as a first-in-class approach to addressing age-related decline in companion animals and reinforced the programme’s relevance to prospective animal health partners.

Genflow said it was actively engaging with animal health companies regarding potential licensing, co-development and commercialisation opportunities.

Dr Eric Leire, chief executive of Genflow, said: "These preliminary interim results represent a significant milestone for Genflow and significantly strengthen our position for animal health partnerships.

"The consistency of positive signals across multiple independent endpoints from survival and quality of life to measures of muscle preservation and frailty reduction, combined with an excellent safety profile, supports our SIRT6 platform as a credible, differentiated asset for the companion animal market."

Leire said that, based on the encouraging preliminary findings, the company was proceeding with the follow-up phase to assess durability of effects and to monitor for differences in age-related disease emergence, data that would inform future commercial discussions.

Genflow expects to provide a comprehensive update on all endpoints, including the critical methylation clock and muscle histology data, within two months.

This week will be very interesting in run up to the GM 2nd March, and I'm not expecting too much downward pressure, and with Genflow fully funded thereafter, the stunning preliminary efficacy data from the Dog Trial will no doubt be fully appreciated. Can't wait!!! Gla holders :-)

I did notice that Rooster, and obviously a shame for such a LTH known for his invaluable contribution to have moved on, and if he has then i wish him well. Perhaps stop losses were triggered and/or took fight or wrong footed at the 40% drop, as I'm sure many others did, and probably regret given the recovery in sp on the same day. No doubt a few are hoping to get back in once we have clarifiation on proposed funding 2nd March, with many hoping for a much lower entry point than current sp, which is conceivably possible, although personally I'm not expecting too much downward pressure on sp in run up to news, as i think the seller is done and given Genflow will be fully funded , expected at market value according to pickpecked's response from IR, the higher the sp the more cash in Genflow's coffers , and we could also have details of new investor(s ), which could be highly significant, and then the patent UPdate 18th March, and a tranche of the €4m non-dilutive grant money by May, as well as the eagerly awaited endpoint data from the Dog Trial, and then the prospect of a game-changing lucrative commercial licensing deal from one of the Animal Healthcare companies if the endpoint data corresponds to the stunning preliminary efficacy data. A very exciting period ahead and no doubt due diligence well under way, possibly on several fronts. Genflow are all set for a major re-rate or two imho...Gl :-)

EP4630038 - VARIANTS OF SIRTUIN 6 FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE [Right-click to bookmark this link]

Status Request for examination was made

Status updated on 12.09.2025

Database last updated on 21.02.2026

Most recent event Tooltip 13.02.2026

Change: Validation states published on 18.03.2026 [2026/12]

13.02.2026 Change - extension states

published on 18.03.2026 [2026/12]

Applicant(s) For all designated states

Genflow Biosciences Srl

Rue Auguste Piccard 48

6041 Charleroi / BE

[2025/42]

Inventor(s) 01 / VINCIGUERRA, Manlio

Liverpool Merseyside L2 2ER / GB

02 / LEIRE, Eric

1170 Watermael-Boitsfort / BE

EP About this file - European Patent Register htTps://share.google/RekVYEtCf241QKxdS

Genflow Biosciences (LON:G... + 2,282 followers 1d.G

Safety comes first in #biotech - and at Genflow Biosciences (LON:GENF) (OTCQB:GENFF) it remains our primary focus.

We've developed patent-pending technology designed to improve safety across our Centenarian #SIRT6 research

Explore Genflow's approach: https://loom.ly/qLRb1jE

Hi Porter, hope you're well mate, are you still here or did you get wiped out your stop loss after the 40% drop??? Haven't seen you since then , which is a real shame considering your usual appreciated input🤔😐

Just managed /struggled to accumulate 1m plus shares today, despite the fact we 've had someone off loading a few for a number of weeks ( I'm convinced it must be Premier Miton, given their current circumstances) and the uncertainty of the proposed private placement (s) which will be clarified 2nd March, which is obviously holding back the sp until the details are announced, as I reckon any downturn from here would be short lived by the time we get disclosure. If it is Premier Miton offloading their 4.3% , then I reckon they must be near enough done, orderly sells and an orderly exit before the GM, and so a clear runway for the sp with Genflow fully funded and the prospect of a tranche of the €4m anytime thereafter ( May at the latest ), by which time we should have full comprehensive efficacy data endpoints from the Dog Trial, and if they follow on from the stunning preliminary efficacy data, then Game on, potential suitors will be queuing UP!!! Gla holders...Excitement building and potential company defining multiple material newsflow, fast approaching!!! :-)

Maybe orderly sells i reckon, we had a few large sells prior to the funding RNS and so fairly certain a TR1 from Premier Miton is very likely, given their negative Q4 2025. Shouldn't be too long before they're done, in time for a Major re-rate on funding clarification 2nd March. The efficacy data on the dog trial was absolutely stunning, better than expected, and yes indeed Steg, a bidding war could be in the pipeline. A very exciting period ahead for all invested. Gla :-)

Premier Milton confirmed by TR1 15th January 25 they had reduced their holding from 9.1% to 4.3% , probably to balance their books, and by the looks of it could be the one whose been off loading a few, over the last month or so. Gla :-)

15/1/26

Premier Miton drops as outflows from equity strategies worsen

Premier Miton Group PLC -

Shares in Premier Miton Group PLC (AIM:PMI) dropped 10.3% to 52.36p after the asset manager reported a 7% decline in assets under management for the first quarter of its financial year.

AuM fell to £9.6 billion as at 31 December 2025, down from £10.3 billion at the end of September.

The group recorded net outflows of around £870 million during the quarter, driven by continued redemptions from US and European equity strategies and outflows from UK multi-cap strategies. Of the total outflows, £119 million was related to corporate actions and capital returned from two investment trusts.

This was larger than the entire previous year's total net outflows of £618 million and £318 million the year before.

Chief executive Mike O'Shea said: "The group's AuM ended the quarter at £9.6 billion, a decrease of 7% on the opening position for the period."

He added: "As noted in our recent full‑year trading update, the outflows from our US and European equity strategies continued into the current period, reflecting investor risk aversion and the rotation away from growth‑oriented equities seen over recent quarters."

There was continued strength in fixed income strategies, which saw net inflows of £163 million.

The company also said it is in advanced discussions to onboard an absolute return institutional mandate, expected to fund with around $80 million before the end of the next quarter.

That should read, "first time I've taken time to properly look at Simply Wall Street.

Thanks for that pickedpeck, first time I've taken a screenshot of the long list of shareholders, and so will be interesting to see any changes in the coming weeks if no Tr1 appears. I see Longevity Technology are down to 1.65% from their previous published 3%, but all in the mix regardless, and whoever has been offloading, it's no concern from me and no reflection on Genflow's prospects and potential going forward. The next few months could be company defining and a clear runway ahead, once the proposed funding is determined and clarified 2nd March. Gl ;-)

Ps pickedpeck, I know Abrdn own ii, so wherever the 11% figure comes from, perhaps it includes those held by pi's on the ii trading platform, whereby I hold a fair few???

Hi pickedpeck, I didn't realise Abrdn held so many shares, I know unofficially it was reported May 25 that Aberdeen Angus held 2.6% , but I've seen nothing since reporting they now hold 11%, then same amount Jonathan Swann has accumulated so far???